IMR Press / EJGO / Volume 35 / Issue 1 / DOI: 10.12892/ejgo23362014

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Evaluation of serum CA 125 level and its relation to surgical, histopathologic and ultrasonographic findings in patients with pelvic mass
Show Less
1 Department of Obstetrics and Gynecology, Shahid Sadoughi University of Medical Science, Yazd
2 Department of Obstetrics & Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd
3 Scientific Association, Yazd Branch, Islamic Azad University, Yazd
4 Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd (Iran)
Eur. J. Gynaecol. Oncol. 2014, 35(1), 67–71;
Published: 10 February 2014

Objective: The aim of this study was to determine the relationship between the levels of tumour marker CA 125 antigen and pelvic tumour size, histopathological type, stage, bilateral status, ascites, type of surgery, and postoperative complications. Materials and Methods: A retrospective cross-sectional descriptive study was conducted on 203 patients with a pelvic mass who were visited in the Shahid Sadoughi hospital in Yazd, Iran from 2007 to 2010. Data were analyzed by software SPSS v.14. Results: Statistical analysis, based on Fisher’s exact test, showed that patients with pelvic mass who presented with either of bilateral involvement/ ascites (p = 0.000), higher stage (p = 0.001), inability for complete resection (p = 0.000), or postoperative complications (p = 0.001) had significantly higher serum concentrations of CA 125 antigen. There was no relationship between serum level of CA 125 and such variables as tumor size (p = 0.883) and abdominal ultrasound findings (p = 0.297). Conclusion: Using CA 125 as a diagnostic and prognostic tool in patients with newly-discovered pelvic mass can be helpful in some aspects, but cannot estimate size of the tumor and its solid/cystic status. It also cannot predict post-surgical complications of malignant pelvic masses.
CA 125 antigen
Pelvic neoplasms
Tumour marker
Surgical complication
Back to top